Bristol Myers Squibb secured FDA approval to expand Breyanzi’s indication to include third‑line marginal zone lymphoma, making it the first CAR‑T therapy cleared for this rare, indolent non‑Hodgkin lymphoma. The label extension follows submitted clinical data demonstrating efficacy in a patient population with limited treatment options. BMS framed the approval as a step into an underserved lymphoma subtype and emphasized regulatory precedence for deploying autologous CAR‑T in lower‑grade hematologic malignancies.